Research Papers:

The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer

Bing-Qin Guo and Wen-Qiao Lu _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:30552-30560. https://doi.org/10.18632/oncotarget.25702

Metrics: PDF 1153 views  |   HTML 1822 views  |   ?  


Bing-Qin Guo1 and Wen-Qiao Lu2

1Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Anhui 233003, China

2The Interventional Diagnosis and Treatment Ward, Thoracic Hospital in Shandong Province, Shandong 250013, China

Correspondence to:

Wen-Qiao Lu, email: [email protected]

Keywords: VEGF; ovarian cancer; prognosis

Received: January 19, 2018    Accepted: May 21, 2018    Published: July 17, 2018


Background & aim: At present, numerous reports have shown that high/positive expression of tissue vascular endothelial growth factor (VEGF) may be associated with the prognosis of patients with ovarian cancer. However, their results still remained controversy. Thus, this meta-analysis was designed to analyze and assess the prognostic value of tissue VEGF expression in patients with ovarian cancer.

Method: We searched PubMed, Embase, Cochrane Library and Web of Science to October, 2017. Hazard Ratio (HR) with its 95% confidence intervals (CIs) was used to evaluate the association between high/positive expression of tissue VEGF and the prognosis of ovarian cancer patients. All statistical analyses were performed using standard statistical procedures provided in RevMan 5.2.

Result: A total of 18 studies (including 1145 patients) were included for this meta-analysis. The positive/high expression of tissue VEGF had an obvious association with overall survival (OS) (HR 2.24, 95% CI 1.36–3.70; P=0.002), progression-free survival (PFS) (HR 1.60, 95% CI 1.11–2.31; P=0.01) and disease-free survival (DFS) (HR 3.49, 95% CI 1.27–9.56; P=0.02) of patients with ovarian cancer respectively.

Conclusion: The present meta-analysis indicated that positive/high expression of tissue VEGF may have a close association with survival of ovarian cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25702